<div class="entities" style="line-height: 2.5; direction: ltr">Admission Date:  [**2170-10-5**]              Discharge Date:   [**2170-10-16**]<br><br>Date of Birth:  [**2101-4-18**]             Sex:   M<br><br>Service: MEDICINE<br><br>Allergies:<br>Patient recorded as having No Known Allergies to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Drugs
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>Attending:[**First Name3 (LF) 8790**]<br>Chief Complaint:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br>Major Surgical or Invasive Procedure:<br>Bone Marrow Biopsy<br>Intra-abdominal and axillary Lymphnode Biopsies<br><br><br>History of Present Illness:<br>69 year old [**Location 12189**] only male with a history of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INH
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifampin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyrazinamide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AIDS
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 CD4 156 who is followed by<br>the [**Hospital **] clinic and was recently evaluated on [**2170-10-4**] with<br>epigastric 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and found to have 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 on CT. The<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 is diffuse and achy. He states that he's had<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 x 1 month and recently returned from [**Country 3587**]<br>where he was evaluated and treated with a &quot;medication&quot; that<br>improved his symptoms there. However, he states that it has<br>worsened over the past few days which caused him to seek<br>attention in the [**Hospital **] clinic. He denies nausea, vomiting, or<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. He has mild 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    constipation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. As a result, a CT torso was<br>obtained on [**2170-10-5**] and the preliminary read showed multiple<br>masses suggestive of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Per OMR records, the patient has<br>a long-standing history of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 since [**2164**] but imaging<br>was obtained only recently.<br><br>Based on the results of his CT scan, the patient was referred to<br>the ED for further evaluation. There, his LDH was 1095, uric<br>acid 22.6, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 66, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ALT
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 48, and sodium 129. He was subsequently<br>admitted to OB on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 precautions for further workup of his<br>grossly abnormal CT scan.<br><br>Past Medical History:<br>1. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: Diagnosed in [**2158**]. He did not disclose to his PCP at<br>[**Hospital1 18**], however, his HIV status until [**2165**] at which time he began<br>to see ID for treatment consideration. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ARV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-naive. No OIs<br>2. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pulmonary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. Diagnosed in [**Country 3587**]. Started on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INH
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifampin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyrazinamide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and likely 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Streptomycin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 on [**7-22**],<br><br>[**2170**]. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Streptomycin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was stopped a few weeks later. [**9-20**] 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifampin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br><br>to 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifabutin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 in anticipation of starting antiretroviral therapy.<br><br>3. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Transmetacarpal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    amputation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 ([**2137**] after a machine accident in<br><br>the war in [**Country 37027**])<br>4. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Bilateral
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    inguinal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hernias
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>5. 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Herpes
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Zoster
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br>Social History:<br>Has 17 children. He has a wife in [**Country 3587**]. He denies any<br>history of 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    IV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    drug
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 use. He was born in [**Country 37027**] and lived there<br>for 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    42
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    years
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Duration</span>
</mark>
, moved to [**Country 3587**], and has traveled back and<br>forth yearly to the US since [**2141**]. He denies current tobacco use<br> although he has a 108-pack-year smoking history and the brother<br>whom he lives with smokes approximately 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    four
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    packs
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 of cigarettes<br>a day. He stopped smoking in [**2135**] after a doctor advised him<br>against it. He also said he used to drink heavily although has<br>not used 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    alcohol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 in years. He currently lives with his brother<br>[**Name (NI) 43334**] [**Telephone/Fax (1) 43335**] who also only speaks [**Location 7972**].<br><br><br>Family History:<br>Significant for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coronary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    artery
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 although<br>no reports of premature 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coronary
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    artery
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br><br>Physical Exam:<br>VS: HR 81, BP 117/66, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    O2sat
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 91% on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NRB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    GEN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
: Elderly, ill- appearing in no respiratory distress<br>HEENT: 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    EOMI
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, PERRL, anicteric<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    NECK
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Supple
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
,<br>CHEST: Decreased BS @ L base<br>CV: RRR, S1S2, no m/r/g<br>ABD: Soft/NT/ND, +BS<br>EXT: warm, no c/c/e<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SKIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
: No rashes<br><br><br>Pertinent Results:<br>[**2170-10-4**] 12:20PM<br>URIC 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-21.5*<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LIPASE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-33<br>ALT(SGPT)-59* AST(SGOT)-83* LD(LDH)-1135*<br>ALK PHOS-125* AMYLASE-78 TOT 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BILI
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-0.2<br>.<br>[**2170-10-5**] 05:20PM<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    URINE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
  BLOOD-NEG NITRITE-NEG PROTEIN-NEG GLUCOSE-NEG KETONE-NEG<br>BILIRUBIN-NEG UROBILNGN-NEG PH-6.5 LEUK-NEG<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    COLOR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Yellow
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 APPEAR-Clear 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SP
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 [**Last Name (un) 155**]-1.013<br>[**2170-10-5**] 05:20PM<br>PT-13.4 PTT-29.1 INR(PT)-1.2*<br>PLT SMR-NORMAL PLT COUNT-343<br>HYPOCHROM-NORMAL ANISOCYT-NORMAL POIKILOCY-NORMAL<br>MACROCYT-NORMAL MICROCYT-NORMAL POLYCHROM-NORMAL<br>NEUTS-37* BANDS-1 LYMPHS-27 MONOS-3 EOS-32* BASOS-0<br>ATYPS-0 METAS-0 MYELOS-0<br>WBC-6.2 RBC-3.02* HGB-9.3* HCT-27.9* MCV-92 MCH-30.7 MCHC-33.3<br>RDW-15.3<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ALBUMIN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-3.5 CALCIUM-8.9 PHOSPHATE-4.6* MAGNESIUM-1.8 URIC<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ACID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    22
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    .
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    6
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
*<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LIPASE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-33<br>ALT(SGPT)-48* AST(SGOT)-66* LD(LDH)-1095* ALK PHOS-123* TOT<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BILI
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
0.2<br>GLUCOSE-114* UREA N-16 CREAT-1.2 SODIUM-129* POTASSIUM-4.1<br>CHLORIDE-97 TOTAL CO2-23 ANION GAP-13<br>.<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CT
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ABDOMEN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 W/
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CONTRAST
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 Study Date of [**2170-10-4**] 3:00 PM<br>IMPRESSION:<br>1. Bilateral diffuse tree-in-[**Male First Name (un) 239**] densities which are compatible<br>with the<br>patient's diagnosis of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. No cavitary lesion is noted.<br>2. Anterior mediastinal, mesenteric and pelvic nodal masses<br>compatible with the diagnosis of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    high
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
- grade 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>3. Multiple small hypodense liver lesions and kidney lesions are<br>too small to characterize.<br>.<br>SPECIMEN SUBMITTED: 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BONE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 MARROW BIOPSY<br>Procedure date     Tissue received     Report Date    Diagnosed<br>by<br>[**2170-10-6**] [**2170-10-7**] [**2170-10-19**] DR. [**Last Name (STitle) **] [**Last Name (NamePattern4) 3157**]/vf<br>Previous biopsies:    [**-8/3863**]  LEFT AXILLARY LYMPH NODE.<br>  [**-8/3862**]  immunophenotyping; BM<br> ==============    DIAGNOSIS     ============<br>SPECIMEN: BONE MARROW 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ASPIRATE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 AND 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CORE
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    BIOPSY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
:<br>DIAGNOSIS:<br>MARKEDLY HYPERCELLULAR BONE MARROW WITH PROMINENT EOSINOPHILS<br>AND SCATTERED 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    LYMPHOHISTIOCYTIC
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AGGREGATES
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. SEE NOTE.<br>Note: There is no morphological evidence of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. Special<br>stains for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    acid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 fast (AFB) and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fungal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 (PAS, GMS) organisms are<br>negative. Immunostains for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    CMV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HSV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 [**1-3**] are negative as<br>well.<br>Pathology Examination<br>.<br>Name Birthdate    Age     Sex Pathology #     [**Hospital1 18**] [**Known lastname 43336**],[**Known firstname **] [**Last Name (NamePattern1) 43337**]       [**2101-4-18**]    69 Male      [**-8/3899**]<br>[**Numeric Identifier 43338**]<br>SPECIMEN SUBMITTED: Immunophenotyping, Lymph Node<br>Procedure date     Tissue received     Report Date    Diagnosed<br>by<br>[**2170-10-9**] [**2170-10-9**] [**2170-10-19**] DR. [**Last Name (STitle) **] [**Last Name (NamePattern4) 3157**]/tk??????<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INTERPRETATION
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>The immunophenotypic findings in conjunction with histological<br>and immunohistochemical studies are consistent with a diagnosis<br>of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    plasmablastic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 (HHV8 negative subtype) .<br>.<br>CHEST (PORTABLE AP) Study Date of [**2170-10-9**] 2:21 PM<br>FINDINGS: In comparison with the study of [**10-8**], there has been<br>placement of an 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    endotracheal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tube
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Route</span>
</mark>
 with its tip approximately 3<br>cm above the carina. Left subclavian catheter extends to the<br>mid-to-lower portion of the SVC. Patchy areas of opacification<br>again seen, especially in the right upper zone.  
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Haziness
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 of the<br>left and also probably right bases could reflect free pleural<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fluid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.<br>.<br>Portable TTE (Complete) Done [**2170-10-10**] at 10:46:11 AM<br>The left atrium is mildly dilated. The estimated right atrial<br>pressure is 0-5 mmHg. Left ventricular wall thickness, cavity<br>size and regional/global systolic function are normal (LVEF<br>60-70%). Tissue Doppler imaging suggests a normal left<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ventricular
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    filling
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 pressure (PCWP&lt;12mmHg). There is no<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ventricular
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    septal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    defect
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. The right ventricular cavity is<br>dilated with normal free wall contractility. The aortic valve<br>leaflets (3) appear structurally normal with good leaflet<br>excursion and no aortic regurgitation. The mitral valve leaflets<br>are structurally normal. There is no mitral valve prolapse. Mild<br>(1+) 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mitral
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    regurgitation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 is seen. There is moderate pulmonary<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    artery
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    systolic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. There is a trivial/physiologic<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pericardial
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    effusion
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. There are no echocardiographic signs of<br>tamponade.<br>.<br>[**2170-10-16**] 12:00AM BLOOD<br>WBC-3.3* RBC-2.52* Hgb-8.3* Hct-23.5* MCV-93 MCH-33.0*<br>MCHC-35.4* RDW-17.7* Plt Ct-336<br>PT-12.7 PTT-39.6* INR(PT)-1.1<br>Glucose-151* 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    UreaN
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-26* Creat-0.8 Na-131* K-4.0 Cl-101 HCO3-23<br>AnGap-11<br>ALT-74* AST-90* LD(LDH)-1801* AlkPhos-102 TotBili-0.4<br><br>Brief Hospital Course:<br>Mr. [**Known lastname **] is a 69 year old [**Location 7972**] man with active<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 (on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INH
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rifampin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pyrazinamide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
), HIV (last CD4<br>count 156 on [**2170-9-20**]) who was recently evaluated for epigastric<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 and was found to have a CT demonstrating<br>mediastinal, mesenteric, and pelvic nodal masses compatible with<br>high
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
grade 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.<br>.<br># Abdominal Pain/Lymphadenopathy:  Pt presented with diffuse and<br>achy 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, which he had for the preceding month. He<br>went to the infectious disease clinic, where he had been<br>followed for his 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. A CT torso was performed<br>on [**2170-10-5**], with preliminary read showing multiple masses<br>suggestive of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
. He was referred to the ED for<br>evaluation; his LDH was 1095 and 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    uric
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 acid 22.6. He was admitted<br>to the [**Hospital Ward Name 516**] hospitalists and rapidly transferred to the<br>BMT service for further management.  A bone marrow biopsy was<br>obtained surgery was emergently consulted for to obtain tissue.<br>The patiet underwent a mini ex-lap and axillary lymphnode<br>disection for biopsy.  Both bone marrow and abdominal lymphnode<br>biopsies demonstrated 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    plasmablastic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  The patient was<br>started on [**Hospital1 **] and tolerated the treatment well.  He was<br>discharged with instructions to follow-up with the hematology<br>clinic.<br>.<br># 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tumor
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lysis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-ADE</span>
</mark>
 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    syndrome
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-ADE</span>
</mark>
/
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    methemoglobinemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
: The patient was<br>admitted with concern- Check 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tumor
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lysis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  The renal team was<br>consulted on [**10-8**] for spontaneous tumor lysis syndrome, with<br>specific question of prophylactic hemodialysis, and recommended<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rasburicase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 to 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    decrease
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    serum
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    uric
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    acid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Allopurinol
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was<br>continued.<br>On [**10-8**] in the evening, Mr. [**Known lastname **] [**Last Name (Titles) 7600**] for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 with<br>desaturations to the 80's. He was given 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    20mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
 x 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 with<br>minimal improvement and was transferred to the ICU.  A<br>discrepancy was noted between his 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    oxygen
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 saturations and PaO2 on<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ABG
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
. Methemoglobin level was noted to be elevated at 10%.<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rasburicase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 was held given its known association with<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    methemoglobinemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.<br>.<br># Tuberculosis/Eosinophilia/HIV: Infectious disease was<br>consulted for help with management of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, HIV, and<br>possible 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    parasitic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 given elevated eosinophilia; they<br>recommended continuing treatment for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 and treating<br>for possible 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    parasitic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ivermectin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 x 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
.<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Charcot
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
-[**Location (un) 5244**] crystals were seen in the stool, which was<br>thought to be secondary to successful treatment of intestinal<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    parasites
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  The patient was continued on 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    therapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 with 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INH
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PZA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    rifabutin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  Sputum from [**9-27**] had been positive for minimal<br>AFB, concerning for either profound 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    immunosuppression
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
,<br>noncompliance, and/or MDR 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  MTD testing was negative for M.<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 on [**10-3**].  The patient was continued on TB therapy.<br>Induced sputum samples from [**10-10**] and [**10-12**] were negative for 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    AFB
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>on gram stain.  Repeat cultures were obtained on [**10-15**] and were<br>pending at the time of discharge.<br>Regarding the patient's HIV, the patient was 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ARV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 naive.  His<br>last CD 4 156 with VL 489,000.  Due to the need for<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
, it was felt that 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ARV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 therapy should be postponed.<br>Upon discharge, the patient was scheduled for follow-up with the<br>ID. clinic.<br>.<br># Thrush: Several days following his inital 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
<br>treatment, the patient was noted to have the [**Last Name (un) **] appearance of<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    oral
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrush
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.   He was started on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nystatin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 with instructions to<br>complete an outpatient treatment course.<br>.<br># 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Inguinal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Hernia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
:  Pt complained of intermittant abdominal pain<br>when standing or 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    coughing
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  On further exam, the patient was<br>note to have 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    bilateral
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    inguninal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    herias
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  Surgery was consulted<br>for concer for infarction.  However, bith inguinal hernias were<br>reduced without difficulty.  No further interventions were<br>taken.<br><br><br>Medications on Admission:<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Isoniazid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    300
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyrazinamide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1000
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifabutin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    300
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyridoxine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    100
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Bactrim
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    SS
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Ketoconazole
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    cream
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
<br><br>Discharge Medications:<br>1. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Isoniazid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    300
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    One
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 (
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
).<br><br>2. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyrazinamide
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    500
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Two
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>(
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
).<br>3. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Rifabutin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    150
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Capsule
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Two
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Capsule
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>(
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
).<br>4. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Pyridoxine
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    50
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Two
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 (
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
).<br><br>5. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Folic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    One
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    1
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
).<br>Disp:*30 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
(s)* Refills:*2*<br>6. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Nystatin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    100
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ,
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    000
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    unit
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    /
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mL
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Suspension
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Five
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    5
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ML
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    TID
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
<br>(
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    3
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    times
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    a
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    day
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
) 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    for
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    7
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    days
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Duration</span>
</mark>
.<br>Disp:*105 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ML
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
(
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    s
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
)* Refills:*0*<br>7. 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Trimethoprim
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Sulfamethoxazole
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    160
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>

<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    800
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 Sig: 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    One
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Dosage</span>
</mark>
 (1)<br>
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    PO
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    DAILY
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
).<br>Disp:*30 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tablet
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
(s)* Refills:*2*<br><br><br>Discharge Disposition:<br>Home With Service<br><br>Facility:<br>[**Location (un) 86**] 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    VNA
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br>Discharge Diagnosis:<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Plasmablastic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Tuberculosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br><br><br>Discharge Condition:<br>The patient was hemodynamically stable, afebrile and without<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
 at the time of discharge.<br><br><br>Discharge Instructions:<br>You were admitted for evaluation of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  You<br>underwent a bone marrow biopsy and biopsy of lymphnodes which<br>showed that you had a type of cancer known as 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lymphoma
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  You<br>underwent 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 treatment for this cancer and will<br>require close follow-up for additional treatment.  You have an<br>appointment scheduled in the [**Hospital **] clinic tomorrow, [**10-17**].<br>You will be contact[**Name (NI) **] regarding the timing of this appointment.<br>.<br>You are scheduled for a follow-up appointment with Dr. [**Last Name (STitle) **]<br>in the Infectious disease clinic on Thursday.  You should<br>continue to wear a mask when in public and at any return visit<br>to the hospital.<br>.<br>We have made several changes to your medications during this<br>hospitalization<br># 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Bactrim
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 (
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antibiotic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
) we have changed the dose of this<br>medication from 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    single
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    strength
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 to 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    double
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Dosage</span>
</mark>
 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    strength
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
.  When you<br>return home, please make sure you are taking the new medication.<br># 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Folic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Acid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    -
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    (
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vitamin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>

<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    )
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
.  Because of your 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
, we have started you on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    folic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    acid
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Drug</span>
</mark>
.  Please take this<br>medication as directed.<br># 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Nystatin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(155, 89, 182); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Solution
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Form</span>
</mark>
- (
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    antifungal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
). This is to treat a 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    yeast
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    infection
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    in
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    your
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mouth
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  You will need to take this medication<br>
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    for
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    at
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    least
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    7
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    days
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Duration</span>
</mark>
 or as instructed by your doctor.<br>.<br>Please continue to take all previously prescribed medications.<br>Please take all medications as directed.<br>.<br>You should call your doctor or seek immediate medical attention<br>if you develop 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    fevers
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chills
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
, 
<mark class="entity" style="background: rgb(94, 164, 80); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-ADE</span>
</mark>
,<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    abdominal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    chest
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pain
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    shortness
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    breath
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 or any other<br>symptom of concern<br><br>Followup Instructions:<br>Provider: [**Last Name (NamePattern4) **]. [**First Name (STitle) **] [**Doctor Last Name 9406**]<br>Phone:[**Telephone/Fax (1) 457**]<br>Date/Time:[**2170-10-18**] 9:30<br>.<br>[**Hospital **] clinic/Dr. [**Last Name (STitle) **]: [**2170-10-17**]<br>([**Telephone/Fax (1) 11576**]<br><br><br><br>Completed by:[**2170-10-22**]</div>